News

Article

Measuring biomarkers may Identify patients at risk of retinal vascular progression after cataract surgery

Author(s):

Investigators wanted to determine why patients who have retinal diseases such as diabetic retinopathy (DR) or age-related macular degeneration (AMD) can undergo cataract surgeries without experiencing a worsening of their retinal disease, while some patients do.

(Image Credit: AdobeStock/Alessandro Grandini)

(Image Credit: AdobeStock/Alessandro Grandini)

Pre-existing levels of vascular endothelial growth factor (VEGF) may predispose certain patients who undergo cataract surgery to develop a retinal pathology postoperatively, reported Naren Shetty, MS, who described the study at the American Society of Cataract and Refractive Surgery annual meeting in Boston.1 Shetty is from Narayana Nethralaya Eye Hospital, Bangalore, India.

He and his colleagues pointed out that while patients who have retinal diseases such as diabetic retinopathy (DR) or age-related macular degeneration (AMD) can undergo cataract surgeries without experiencing a worsening of their retinal disease, some patients do experience worsening. The investigators wanted to determine why that occurs.

To do so, they collected samples of aqueous humor from patients who were undergoing cataract surgeries. Optical coherence tomography was performed preoperatively in all patients and patients found to have non-proliferative and proliferative DR were not included.

The investigators recorded the patients’ diabetic, DR, and hypertension status and followed the patients for 6 to 12 months. They reported conducting testing of a panel of 8 markers on each aqueous humor sample.

In 42 eyes tested, the retinal pathology increased in 5 eyes; Shetty described this as progression to moderate or severe non-proliferative DR and development of diabetic macular edema (DME) compared to the eyes that remained stable.

He and his colleagues reported, “The levels of VEGF in the group with progressive retinal pathology were significantly higher (p<0.05) compared to the group without progressive retinal pathology at the time of cataract surgery.”

Other markers such as interleukin (IL)-6, -10, -1b, and -17A; tumor necrosis factor-a; matrix metalloproteinase 9; and soluble intercellular adhesion molecule-1 did not show significant differences.

The investigators believe that the levels of VEGF present at the time of cataract surgery may result in development of detrimental retinal pathology postoperatively. “Using biomarker testing to stratify patients to enable close monitoring or prophylactic care may help reduce the risk of DME postoperatively,” they concluded.

  1. Conference Abstract or Poster
    Shetty N, Shetty R, Khamar P,et al. Novel biomarker levels to identify risk of retinal vascular progression post cataract surgery. Paper presented at: American Society of Cataract and Refractive Surgery 2024 annual meeting; April 5-8, 2024; Boston, Massachusetts, USA. Session: SPS-202 Retina

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.